Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Budesonide/Formoterol Inhalation Powder in Healthy Participants
NCT07804303Phase 1Completed
- Sponsor
- Shanghai Xin Huanghe Pharmaceutical
- Start
- Jan 2024
- Primary completion
- Jan 2024
- Countries
- 1
01
Overview
Phase 1, randomised trial of budesonide and formoterol in asthma and chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Shanghai Xin Huanghe Pharmaceutical. Primary endpoints: Maximum Observed Concentration, Area Under the Plasma Concentration-Time Curve from Time 0 to the Last Measurable Concentration and 1 more. Started Jan 2024; status: completed.
02
Drugs
budesonideformoterol
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07804303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07804303.